Fda-Cms Parallel Review: A Failed Attempt at Spurring Innovation

15 Pages Posted: 7 Jun 2018

Multiple version iconThere are 2 versions of this paper

Date Written: 09/28/2016


In 2010 the Food and Drug Administration and the Centers for Medicare & Medicaid Services (CMS) founded a pilot program for medical devices: simultaneous review of FDA premarket approval submissions and CMS national coverage determinations. By reducing the amount of time between obtaining marketing approval and securing Medicare coverage, the parallel-review program is supposed to facilitate the development of innovative medical devices and to shorten the time it takes to bring these devices to patients. After five years, however, the program’s impact remains limited: so far, only one device has been approved through this process. Why are manufacturers not more interested in this opportunity? While parallel review might shorten time to national coverage determination, it is likely to delay marketing of the device. Moreover, while meant to promote innovation, parallel review does not address key obstacles manufacturers currently encounter in bringing their products to market.

Suggested Citation

Podemska-Mikluch, Marta, Fda-Cms Parallel Review: A Failed Attempt at Spurring Innovation (09/28/2016). MERCATUS WORKING PAPER, Available at SSRN: https://ssrn.com/abstract=3191386 or http://dx.doi.org/10.2139/ssrn.3191386

Marta Podemska-Mikluch (Contact Author)

Gustavus Adolphus College ( email )

800 West College Ave.
Saint Peter, MN Mn 56082
United States
(507) 933-6120 (Phone)

HOME PAGE: http://www.podemska.com

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Abstract Views
PlumX Metrics